Roivant Sciences Analyst Price Targets - Benzinga

Roivant Sciences Ltd

ROIVNASDAQ

Trade with Public

Trade with Public

$35.80

-0.33-0.91%

가까이에: Sep 24, 5:00 PM EST

$35.60

-0.53-1.47%

프리마켓: 8:01 AM EST

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Roivant Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Roivant Sciences (ROIV).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

14Buy

1Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$34Upside to Avg. PT-3.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 17, 2026	Stifel	Alex Thompson	Initiate	Buy	$51
Sep 9, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$50→$55
Sep 9, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$42→$46
Sep 8, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$41→$47
Sep 8, 2026	Jefferies	Dennis Ding	PT Raise	Buy	$42→$52
Aug 28, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$41
Aug 10, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$42→$46
Aug 7, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$36→$42
Aug 7, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$34→$41
May 26, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$30→$36
May 21, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$35→$42
May 21, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$38→$41
May 21, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$34
Apr 16, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$22→$40
Mar 4, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$33→$34
Feb 10, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$26→$35
Feb 10, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$26→$33
Feb 9, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$28→$30
Dec 15, 2025	Leerink Partners	David Risinger	PT Raise	Outperform	$29→$32
Dec 15, 2025	Goldman Sachs	Corinne Jenkins	PT Raise	Buy	$24→$33

More with Benzinga EdgeGet Access

Analyst Ratings News

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.

Avi Kapoor

PRO
Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51

Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $51.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55

TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $50 to $55.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $46

Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $46.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $47

HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $41 to $47.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Roivant Sciences, Raises Price Target to $52

Jefferies analyst Dennis Ding maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $52.

Benzinga Newsdesk